title: Biopharmaceuticals: recent approvals and likely directions.
abstract: Some 160 biopharmaceuticals have now gained medical approval and several hundred are in the pipeline. Most are protein-based, although two nucleic acid-based products are now on the US/European market. An increasing proportion of approvals are engineered in some way and advances in alternative production systems and delivery methods will also likely impact upon the approvals profile over the remainder of this decade.
authors.affiliation: Industrial Biochemistry Program, University of Limerick, Castletroy, Limerick City, Ireland. Gary.walsh@ul.ie
authors.forename: Gary
authors.initials: G
authors.lastname: Walsh
mesh_terms: D001702:Biopharmaceutics / Q000706:statistics & numerical data / Q000639:trends*; D017277:Drug Approval / Q000706:statistics & numerical data*; D016503:Drug Delivery Systems / Q000706:statistics & numerical data / Q000639:trends*; D004345:Drug Industry / Q000639:trends*; D005060:Europe; D005544:Forecasting; D009696:Nucleic Acids / Q000627:therapeutic use*; D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014481:United States
chemical_list: D009696:Nucleic Acids; D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins